News Join our mailing list to receive our quarterly email newsletter with news, updates and events in bowel management. SUBSCRIBE AllCancerCoeliac DiseaseConstipationIncontinenceIBSInflammatory Bowel DiseasePaediatricsEuropean Commission grants marketing authorisation for Remsima® SC in Crohn’s disease & ulcerative colitis.July 27, 2020New study into link between IBD and colorectal cancersJuly 22, 2020The BSG issues interim guidance for diagnosing coeliac disease without biopsyJuly 13, 2020Enhertu granted Breakthrough Therapy Designation in the US for HER2-positive metastatic gastric cancerMay 13, 2020Entyvio® (Vedolizumab) receives marketing authorisation for Ulcerative Colitis & Crohn’s DiseaseMay 13, 2020NICE positive FAD recommends STELARA® for ulcerative colitisApril 28, 2020NICE publish COVID-19 rapid guideline for gastrointestinal conditionsApril 23, 2020SMC accepts STELARA® for ulcerative colitis treatment in ScotlandApril 15, 2020Coeliac UK launches appeal to keep support going for thousands with autoimmune diseaseApril 6, 2020AI chatbot partners with pharma to support IBD patients during Covid-19April 6, 2020Takeda Receives Positive CHMP Opinion for Subcutaneous Formulation of Vedolizumab in Ulcerative Colitis or Crohn’s DiseaseMarch 6, 2020NICE updates guidance for colorectal cancerFebruary 24, 20204 1234567 5
European Commission grants marketing authorisation for Remsima® SC in Crohn’s disease & ulcerative colitis.July 27, 2020
Enhertu granted Breakthrough Therapy Designation in the US for HER2-positive metastatic gastric cancerMay 13, 2020
Entyvio® (Vedolizumab) receives marketing authorisation for Ulcerative Colitis & Crohn’s DiseaseMay 13, 2020
Takeda Receives Positive CHMP Opinion for Subcutaneous Formulation of Vedolizumab in Ulcerative Colitis or Crohn’s DiseaseMarch 6, 2020
